NIKKEI 225
39,658.67 +485.52 (+1.24%) HANG SENG
18,094.35 +21.45 (+0.12%) CRUDE OIL
81.28 +0.45 (+0.56%) GOLD FUTURES
2,328.90 -1.90 (-0.08%) DOW
39,112.16 -299.05 (-0.76%) Bitcoin GBP
48,666.78 +323.79 (+0.67%)
REGN Jul 2024 1050.000 call
| Previous close | 34.68 |
| Open | 38.95 |
| Bid | 32.40 |
| Ask | 39.40 |
| Strike | 1,050.00 |
| Expiry date | 2024-07-19 |
| Day's range | 34.68 - 43.26 |
| Contract range | N/A |
| Volume | |
| Open interest | 70 |
Simply Wall St.Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Could Be 45% Below Their Intrinsic Value Estimate
Key Insights The projected fair value for Regeneron Pharmaceuticals is US$1,936 based on 2 Stage Free Cash Flow to...
ZacksRegeneron (REGN) Outperforms Industry YTD: What Lies Ahead?
Regeneron (REGN) maintains momentum on the back of Dupixent profits and efforts to develop oncology portfolio despite near-term challenges.
GlobeNewswireUpdated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously published in the Journal of Clinical Oncology Also presented at EHA, a retrospective study of patient outcomes that compared investigational linvoseltamab to real-world standard-of-care treatment in clinical practice TARRYTOWN, N.Y., June 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.
